首页> 美国卫生研究院文献>Infection and Immunity >MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine.
【2h】

MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine.

机译:MF59佐剂可增强用b型流感嗜血杆菌和脑膜炎奈瑟氏球菌C组寡糖-CRM197结合疫苗免疫的狒狒的抗体应答。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The ability of the adjuvant MF59 to enhance the immunogenicity of polysaccharide-protein conjugate vaccines was investigated in infant baboons. MF59 consists of stable droplets (<250 nm) of the metabolizable oil squalene and two surfactants, polyoxyethylene sorbitan monooleate and sorbitan trioleate, in an oil-in-water emulsion. In humans, MF59 is well tolerated and enhances the immunogenicity of recombinant protein subunit or particle vaccines. Its effect on the immunogenicity of polysaccharide-protein conjugate vaccines is unknown. Baboons 1 to 4 months of age were immunized intramuscularly with Neisseria meningitidis group C and Haemophilus influenzae type b (Hib) oligosaccharide-CRM197 conjugate vaccines. The lyophilized vaccines were reconstituted with phosphate-buffered saline (PBS), Al(OH)3 (alum), or MF59. Groups of five animals each were given three injections of the respective formulations, with one injection every 4 weeks. Four weeks after each immunization, the MF59 group had up to 7-fold-higher geometric mean anticapsular-antibody titers than the alum group and 5- to 10-fold-higher N. meningitidis group C bactericidal-antibody titers. Twenty-one weeks after the third immunization, the MF59 group still showed 5- to 10-fold-higher anticapsular-antibody titers. The antibody responses of the animals given the vaccines reconstituted with PBS were low at all times measured. Both the MF59 and alum groups, but not the PBS group, showed booster antibody responses to unconjugated Hib and N. meningitidis group C polysaccharides, results consistent with induction of memory B cells. Thus, MF59 may be useful for accelerating and augmenting immunity to polysaccharide-protein conjugate vaccines in infants.
机译:在婴儿狒狒中研究了佐剂MF59增强多糖蛋白偶联疫苗的免疫原性的能力。 MF59由可代谢的油角鲨烯的稳定液滴(<250 nm)和两种表面活性剂(聚氧乙烯脱水山梨醇单油酸酯和脱水山梨糖醇三油酸酯)在水包油乳液中组成。在人类中,MF59具有良好的耐受性,可增强重组蛋白亚基或颗粒疫苗的免疫原性。其对多糖-蛋白质结合疫苗的免疫原性的影响尚不清楚。用脑膜炎奈瑟氏球菌C组和b型流感嗜血杆菌(Hib)寡糖-CRM197结合疫苗肌肉注射1至4个月大的狒狒。将冻干的疫苗用磷酸盐缓冲盐水(PBS),Al(OH)3(alum)或MF59重建。每组五只动物分别注射三剂各自的制剂,每四周注射一次。每次免疫后四周,MF59组的抗囊虫抗体几何平均效价比明矾组高7倍,脑膜炎奈瑟氏球菌C组杀菌抗体的效价高5至10倍。第三次免疫接种二十一周后,MF59组的抗荚膜抗体滴度仍高出5至10倍。给予用PBS重组疫苗的动物的抗体反应在所有时间均较低。 MF59组和明矾组均没有显示出对未结合的Hib和脑膜炎奈瑟氏球菌C组多糖的增强抗体反应,结果与记忆B细胞的诱导一致。因此,MF59可用于加速和增强婴儿对多糖-蛋白质结合疫苗的免疫力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号